क्लिनिकल और सेलुलर इम्यूनोलॉजी जर्नल

क्लिनिकल और सेलुलर इम्यूनोलॉजी जर्नल
खुला एक्सेस

आईएसएसएन: 2155-9899

अमूर्त

Comparison of Primary versus Secondary Effects of Antiphospholipid Syndrome on the Development of Thrombosis

Haneen Sait, Ahmed Saleh, Waleed Alshehri, Mohammed Alsheef

Background: Antiphospholipid syndrome (APS) is an autoantibody-mediated acquired thrombophilia. It is characterized by the presence of antiphospholipid antibodies (APL) that increase the risk of thrombosis.

Objective: To compare primary versus secondary effect of APS on the development of thrombosis and its outcomes.

Design: Retrospective cohort

Setting: Thrombosis clinics at KFMC

Materials and methods: A retrospective chart review from medical and electronic records for all patients who were confirmed to have APS and attended thrombosis clinic from 2009 to 2019 at King Fahad Medical City in Riyadh Saudi Arabia. A total of 100 patients fulfilled our inclusion criteria.Variables collected include thrombotic risk factors and outcomes.

Results: A total of 100 patients were included in the final analysis. Primary APS was present in (67%) and secondary APS was present in (33%). Recurrent of DVT was associated with a 4.8-fold increase the risk of thrombosis in patients with triple positive (p=0.01). DVT progressed to PE was associated with a 3.06-fold increase risk for recurrent thrombosis in general (p=0.03). Unprovoked thrombosis was seen in most of the cases accounting for 89% showing no statistically significant differences between both groups. In pregnancy complications no major difference was observed when comparing both groups.

Conclusion: Based on our retrospective analysis of aPL database shows that thrombosis is greater in primary APS than in APS associated with SLE. However, patients with triple positive demonstrate risk factor of recurrent of DVT. Moreover, DVT progressed to PE was associated with an increased risk of thrombotic in general.

अस्वीकरण: इस सार का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया था और अभी तक इसकी समीक्षा या सत्यापन नहीं किया गया है।
Top